Medication-assisted Treatment (MAT) Market Size & Share, by Treatment Type (Drug Type, Counseling & Therapies); End User (Hospitals, Home Care Setting, Rehabilitation Clinic) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2024-2036

  • Report ID: 5814
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Global Market Size, Forecast, and Trend Highlights Over 2024-2036

Medication-assisted Treatment Market size is poised to reach USD 24.7 Million by the end of 2036, growing at a CAGR of 11.4% during the forecast period, i.e., 2024-2036. In the year 2023, the industry size of medication-assisted treatment was USD 13.3 Million. This can be attributed to the rising prevalence of substance use disorder among individuals. According to recent information, around 286 Million people aged 15-64 used drugs worldwide in 2020, a 26 percent increase over the past decade.

In addition, with the advancement in medications and therapies such as the availability of a variety of medications like methadone, naltrexone. There is a continuous improvement in behavioral therapies and pharmacological treatments which is enhancing the efficacy of medication-assisted treatment. Moreover, the development of long-acting formulations and innovative delivery methods is also driving the medication-assisted treatment market growth.


Medication-assisted Treatment Market overview
Get more information on this report: Request Free Sample PDF

Medication-assisted Treatment Sector: Growth Drivers and Challenges

Growth Drivers

  • Increase in Substance Abuse Deaths- Drug overdose deaths have been increasing rapidly and are among one of the reasons for mortality across the globe. According to the World Health Organization, about 600000 deaths were attributed to drug use in the year 2019. In addition, the rise in substance abuse deaths catalyzes the recognizing the urgency of implementing evidence-based interventions like MAT, leading to increased acceptance, adoption, and growth in the medication-assisted treatment market.  Furthermore, substance abuse often coexists with mental health disorders, contributing to the complexity of treatment. MAT, by addressing both addiction and mental health aspects, becomes a comprehensive solution that stimulates the market.
  • Rising Awareness of Medication-assisted Treatment (MAT)- Health organizations and advocacy groups conduct public education campaigns to spread information about the effectiveness of MAT in treating substance use disorder. In addition, increased media coverage of substance abuse issues and the role of MAT in treatment amplifies awareness. News stories, documentaries, and interviews with experts influence public opinion and encourage individuals to seek medication-assisted treatment when facing addiction challenges which stimulates the market. Furthermore, positive testimonials and success stories from individuals who have benefited from MAT contribute to the growth of the medication-assisted treatment market.   
  • Emergence of Technological Innovation- The integration of digital health tools, such as mobile applications and web platforms, facilities remote monitoring and management of patients undergoing MAT. In addition, the adoption of teleheath services has expanded access to MAT, allowing patients to consult with healthcare professionals virtually. This is particularly valuable for individuals in remote areas which boosts the medication-assisted treatment market. Furthermore, electronic health records systems streamline the management of patient information, ensuring that healthcare providers have comprehensive and up-to-date records. This promotes coordinated care, reduces administrative burdens, and enhances the overall quality of MAT programs.

Challenges

  • Regulatory Challenges across Regions- Regulatory framework and licensing requirements vary across regions, posing challenges to the expansion of medication-assisted treatment services. Integration and harmonization of the regulation process are necessary to overcome these obstacles.
  • Unequal distribution of healthcare resources, particularly in rural and low-income areas, restricts access to medication-assisted treatment.
  • The stigma linked with substance addiction and MAT is a significant hurdle to its adoption. Moreover, the lack of awareness among the general public regarding the implementation of MAT is also a hindrance.

Medication-assisted Treatment (MAT) Market: Key Insights

Base Year

2023

Forecast Year

2024-2036

CAGR

 ~ 11.4%

Base Year Market Size (2023)

~ USD 13.3 Million

Forecast Year Market Size (2036)

~ USD 24.7 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Medication-assisted Treatment Segmentation

 Treatment Type (Drug Type, Counseling & Therapies)

The drug type segment in the medication-assisted treatment market is estimated to gain the largest revenue share of about 56% by 2036. The segment growth can be attributed to the factor that the pharma industry’s innovation in MAT, along with the growing awareness and acceptance of these treatments, further propels the drug-type segment expansion within the market. In addition, the market in the drug type segment is also influenced by the development of medication designed to assist individuals recovering from substance use disorder. According to recent data, substance use disorders cost employer-sponsored health insurance over USD 35 Billion in 2023.

End-User (Hospital, Rehabilitation Clinic, Home Care Setting)

The hospital segment in the medication-assisted treatment market is estimated to gain the largest reevenue share of about 53% in the year 2036. The segment growth can be attributed to the factor that hospitals are integral in providing MAT due to their capacity for specialized care, medical expertise, and resources. In addition, hospitals often offer inpatient MAT programs, providing a controlled and supervised environment for individuals undergoing treatment. This approach allows for intensive medical monitoring and adjustment of medication dosages based on individual needs which stimulate the segment growth.

Our in-depth analysis of the global market includes the following segments:

          Treatment Type

  • Drug Type
  • Counseling & Therapies

          End-User

  • Hospital
  • Rehabilitation Clinic
  • Home Care Setting 

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Medication-assisted Treatment Industry - Regional Synopsis

North American Market Forecast

Medication-assisted Treatment market in the North America region is anticipated to hold the largest share of about 45% by the end of 2036. The regional growth is attributed to the factor that government, healthcare, organizations, and philanthropic entities in the region have allocated increased funding and resources to support MAT initiatives. This financial backing has enabled the expansion of treatment facilities, training programs, and public awareness campaigns. According to the National Institute on Drug Abuse, methadone treatment, including medication and integrated psychosocial & medical support services cost USD 6, 55, 20 per year in the US. In addition, the region has recognized the importance of MAT in treating opioid addiction and regulatory frameworks have been adapted to facilitate the integration of MAT into mainstream healthcare, ensuring better access to these treatments for individuals in need and stimulate the market in the region.

European Market Analysis

The Europe medication-assisted treatment market is estimated to the second largest revenue share of about 30% by the end of 2036. The market’s expansion can be attributed to the multidisciplinary approach adopted by the European healthcare system to deal with substance disorders. MAT is integrated into this approach, combining medications with counseling and psychosocial support to address the complex nature of substance use disorders comprehensively. In addition, Community-based MAT programs have been established in various European regions. For example, a Harm reduction program encompasses interventions and policies that seek to mitigate the health, social, and economic harms of drug use to individuals, communities, and societies.  These initiatives focus on providing localized and accessible treatment options, emphasizing the importance of community involvement and support in the recovery process which further stimulate the medication-assisted treatment market in the region.

Research Nester
Medication-assisted Treatment Market size
Get more information on this report: Request Free Sample PDF

Companies Dominating the Medication-assisted Treatment Landscape

top-features-companies
    • Indivior PLC
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Mallinckrodt Pharmaceuticals
    • Titan Pharmaceuticals, Inc.
    • Alkermes plc
    • Orexo AB
    • Mylan N.V.
    • Teva Pharmaceuticals Industries Ltd.
    • Lupin limited
    • Hikma Pharmaceuticals PLC
    • Novartis AG

In-the-news

In The News

  • December 2023: Alkerems plc announced that it entered into a definitive agreement to sell its development and manufacturing facility in Athlone, Ireland to Novo Nordisk , a leading global healthcare company. In terms of agreement, Alkermes will be entitled to one time cash payment of USD 92.5 Million for the facility and related assets, subject to customary adjustments in accordance with the agreement. In addition, Alkermes and Novo Nordisk also plan to enter into subcontracting arrangements to continue certain work currently performed at the facility for a period of time after closing the transaction, which may continue through the end of 2025.  
  • August 2023: Orexo AB announced that it continues to strengthen its patent portfolio and the new patent , No. US 11,737,980 provides protection for the OX640 product in the US until may 2041.  Moreover, Orexo’s proprietary drug delivery platform , amorphOX, is a powder made up of particles which are built using a unique combination of drug, carrier materials and optionally other ingredients.

Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 5814
  • Published Date: Mar 05, 2024
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Increase in substance abuse deaths, rising awareness of Medical –assisted Treatment (MAT) and emergence of technological innovations are the major factors driving the growth of the medication-assisted treatment market.

The market size of medication-assisted treatment is anticipated to attain a CAGR of 11.4% over the forecast period, i.e., 2024 - 2036.

The major players in the market are Orexo AB, Novartis AG, Mylan N.V., Lupin Limited, Hikma Pharmaceuticals PLC and others.

The drug type segment is anticipated to garner the largest market size by the end of 2036 and display significant growth opportunities.

The market in the North America is projected to hold the largest market share by the end of 2036 and provide more business opportunities in the future.
Medication-assisted Treatment (MAT) Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying